Skip to main content

Menu

BNF for Children November 2024 Update

This update contains 7 significant changes, 5 dose changes, 1 new monograph, and 2 new preparations

Significant Changes:

  • Antibacterials, principles of therapy: update to notifiable diseases reporting.
  • Antibacterials, use for prophylaxis: updated guidance on secondary prevention of meningococcal disease and secondary prevention of pertussis.
  • Borderline substances: oral nutritional supplements have been re-organised in a new section called Oral nutrition.
  • Co-amoxiclav: update to structure of indications and dose section; tablet dose expression changed to co-amoxiclav (total of amoxicillin and clavulanic acid).
  • Immunisation schedule: updated guidance for immunisation against influenza, and for pertussis in pregnancy.
  • Pertussis vaccine: updated guidance for immunisation.
  • Topical corticosteroids: update to the list of topical corticosteroid potencies.

Dose Changes:

  • Ciprofloxacin [indication changed from prevention of secondary case of meningococcal meningitis to prevention of secondary case of meningococcal disease].
  • Ivacaftor [update to dosing].
  • Lithium carbonate [update to dosing].
  • Lithium citrate [update to dosing].
  • Lumacaftor with ivacaftor [update to dosing] .

New Monographs:

  • Mepsevii® [vestronidase alfa].

New Preparations: Co-amoxiclav 1 g (875/125 mg) tablet; Co-amoxiclav 2.2 g (2000/200 mg) infusion.